The functional promoter polymorphism (-842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger.

Abstract:

:PIN1, an isomerase that causes conformational changes in proteins, plays an important role in mammary epithelial cell growth both physiologically and pathologically. Thus, genetic variants in the PIN1 gene may alter protein function and cancer risk. We have previously demonstrated an association between a PIN1 promoter variant (-842G>C; rs2233678) and risk of squamous cell carcinoma of the head and neck, a finding supported by additional functional data. In the present study, we genotyped two promoter single nucleotide polymorphisms (SNPs) (-842G>C, rs2233678 and -667T>C, rs2233679) and one synonymous SNP (Gln33Gln; G>A, rs2233682) in exon 2 to evaluate their associations with risk of sporadic breast cancer in non-Hispanic white women 55 years and younger. We found that the carriers of -842C variant alleles had decreased risk of breast cancer with an adjusted odd ratio (OR) of 0.67 and 95% confidence interval (CI) of 0.50-0.90. This reduced risk was more evident in women after reproductive age of 45 (OR = 0.63, 95% CI = 0.42-0.93), ever-smokers (OR = 0.56, 95% CI = 0.36-0.88), and ever-drinkers (OR = 0.67, 95% CI = 0.45-0.99). No such associations were observed for PIN1 -667T>C and PIN1 Gln33Gln. However, the haplotypes of these three SNPs were also associated with reduced risk of breast cancer. In conclusion, the PIN1 polymorphisms may contribute to the etiology of sporadic breast cancer in non-Hispanic white women 55 years and younger. Further validation in large population-based studies is needed.

authors

Han CH,Lu J,Wei Q,Bondy ML,Brewster AM,Yu TK,Buchholz TA,Arun BK,Wang LE

doi

10.1007/s10549-009-0682-9

subject

Has Abstract

pub_date

2010-07-01 00:00:00

pages

243-9

issue

1

eissn

0167-6806

issn

1573-7217

journal_volume

122

pub_type

杂志文章
  • Improved prognostication in small (pT1) breast cancers by image cytometry.

    abstract::Feulgen-stained samples from 460 small (pT1) primary breast cancers were investigated by means of an image analysis system. Several DNA, morphometrical and textural parameters were evaluated for each patient, and the prognostic meaning of these parameters was then investigated by the Cox regression analysis. As progno...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00690188

    authors: Aubele M,Auer G,Falkmer U,Voss A,Rodenacker K,Rutquist LE,Höfler H

    更新日期:1995-01-01 00:00:00

  • Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance).

    abstract:PURPOSE:To investigate the effects of cognitive function on discontinuation of hormonal therapy in breast cancer survivors ages 65+ ("older"). METHODS:Older breast cancer survivors with invasive, non-metastatic disease, and no reported cognitive difficulties were recruited from 78 Alliance sites between 2004 and 2011....

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s10549-017-4353-y

    authors: Bluethmann SM,Alfano CM,Clapp JD,Luta G,Small BJ,Hurria A,Cohen HJ,Sugarman S,B Muss H,Isaacs C,Mandelblatt JS

    更新日期:2017-10-01 00:00:00

  • Medroxyprogesterone acetate enhances spontaneous mammary tumorigenesis and uterine adenomyosis in mice.

    abstract::Based on our previous findings that medroxyprogesterone acetate (MPA) significantly suppressed the formation of preneoplastic mammary hyperplastic alveolar nodules in mice, and that this suppression persisted for some time, we studied the effects of different schedules of MPA treatment on spontaneous mammary tumorigen...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01805741

    authors: Nagasawa H,Aoki M,Sakagami N,Ishida M

    更新日期:1988-09-01 00:00:00

  • Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.

    abstract:PURPOSE:Homologous recombination (HR)-deficient breast tumors may have genomic alterations that predict response to treatment with PARP inhibitors and other targeted therapies. METHODS:Comprehensive molecular profiles of 4647 breast tumors performed at Caris Life Sciences using 592-gene NGS were reviewed to identify s...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05849-2

    authors: Heeke AL,Xiu J,Elliott A,Korn WM,Lynce F,Pohlmann PR,Isaacs C,Swain SM,Vidal G,Schwartzberg LS,Tan AR

    更新日期:2020-11-01 00:00:00

  • T-bet+ lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer.

    abstract:PURPOSE:T-box transcription factor 21 (T-bet), which is the master regulator of effector T-cell activation, is derived by stimulation of T-cell receptors. In this study, we focused on T-bet and examined the function of activated T cells. METHODS:This study included 242 patients with primary triple-negative breast canc...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05256-2

    authors: Mori H,Kubo M,Kai M,Yamada M,Kurata K,Kawaji H,Kaneshiro K,Osako T,Nishimura R,Arima N,Okido M,Kishimoto J,Oda Y,Nakamura M

    更新日期:2019-08-01 00:00:00

  • Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting.

    abstract:OBJECTIVES:To validate the newly proposed American Joint Committee on Cancer (AJCC) prognostic staging system for breast cancer. METHODS:Surveillance, epidemiology, and end results (SEER) database (2010-2014) was accessed. Cumulative incidence function was conducted (through assessment of sub-distribution hazard) acco...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4577-x

    authors: Abdel-Rahman O

    更新日期:2018-02-01 00:00:00

  • Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells.

    abstract::Aromatase inhibitors (AIs) are used for treatment of estrogen receptor α (ER)-positive breast cancer; however, resistance is a major obstacle for optimal outcome. This preclinical study aimed at identifying potential new treatment targets in AI-resistant breast cancer cells. Parental MCF-7 breast cancer cells and four...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3284-8

    authors: Hole S,Pedersen AM,Lykkesfeldt AE,Yde CW

    更新日期:2015-02-01 00:00:00

  • Vegetable intake is associated with reduced breast cancer recurrence in tamoxifen users: a secondary analysis from the Women's Healthy Eating and Living Study.

    abstract::The protective effect of vegetables on the risk of breast cancer recurrence is uncertain. We sought to evaluate the association between breast cancer recurrence and vegetable intake including analyses stratified on tamoxifen use. Experimental evidence of anti-carcinogenic activity of phytochemicals in cruciferous vege...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1014-9

    authors: Thomson CA,Rock CL,Thompson PA,Caan BJ,Cussler E,Flatt SW,Pierce JP

    更新日期:2011-01-01 00:00:00

  • Pre- and post-diagnostic intake of whole grain and dairy products and breast cancer prognosis: the Danish Diet, Cancer and Health cohort.

    abstract:PURPOSE:Fiber rich foods and dairy products have been suggested to be associated with breast cancer prognosis, though existing research is limited and either report on pre- or post-diagnostic dietary intake in relation to breast cancer prognosis. We investigated the associations between intake of whole grain (WG) and d...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05497-1

    authors: Andersen JLM,Hansen L,Thomsen BLR,Christiansen LR,Dragsted LO,Olsen A

    更新日期:2020-02-01 00:00:00

  • Molecular determinants of drug response in TNBC cell lines.

    abstract:PURPOSE:There is a need for biomarkers of drug efficacy for targeted therapies in triple-negative breast cancer (TNBC). As a step toward this, we identify multi-omic molecular determinants of anti-TNBC efficacy in cell lines for a panel of oncology drugs. METHODS:Using 23 TNBC cell lines, drug sensitivity scores (DSS3...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05473-9

    authors: Merrill NM,Lachacz EJ,Vandecan NM,Ulintz PJ,Bao L,Lloyd JP,Yates JA,Morikawa A,Merajver SD,Soellner MB

    更新日期:2020-01-01 00:00:00

  • Erratum to: Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients.

    abstract::Erratum to: Breast Cancer Res Treat (2012),134:549–560,DOI 10.1007/s10549-012-2080-y. In the original publication of the article, Fig. 5c was published incorrectly. The authors apologize for this error and the correct Fig. 5c is given below. ...

    journal_title:Breast cancer research and treatment

    pub_type: 已发布勘误

    doi:10.1007/s10549-016-3703-5

    authors: Tang J,Deng R,Luo RZ,Shen GP,Cai MY,Du ZM,Jiang S,Yang MT,Fu JH,Zhu XF

    更新日期:2016-04-01 00:00:00

  • Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine).

    abstract::The aim of this study was to compare the effects on health-related quality of life (HRQOL) of two treatment regimens in the TEX trial during 9 month from random assignment, with emphasis on the 2- and 9-months assessments. A total of 287 patients were randomized to treatment in 3-week cycles with either epirubicin plu...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-010-1084-8

    authors: Svensson H,Einbeigi Z,Johansson H,Hatschek T,Brandberg Y

    更新日期:2010-10-01 00:00:00

  • Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database.

    abstract:PURPOSE:To evaluate the effect of adjuvant chemotherapy on improving the prognosis of patients with stage I triple-negative breast cancer (TNBC). METHODS:TNBC patients diagnosed in the SEER 18 database from 2010 to 2015 were included. Kaplan-Meier plots and log-rank tests were used to compare the differences in breast...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05776-2

    authors: Du ZL,Wang Y,Wang DY,Zhang L,Bian ZM,Deng Y,Xu CS,Lin DC,Xie L,Jia Y,Gao JD,Zhang BL

    更新日期:2020-09-01 00:00:00

  • Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women.

    abstract::Beta-blockers (BB) drugs have been used for decades worldwide, mainly to treat hypertension. However, in recent epidemiological studies, BBs were suggested to improve cancer prognosis. In the wake of this evidence, we evaluated the possible therapeutic effect of BBs in triple-negative breast cancer (TNBC) patients. We...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2654-3

    authors: Botteri E,Munzone E,Rotmensz N,Cipolla C,De Giorgi V,Santillo B,Zanelotti A,Adamoli L,Colleoni M,Viale G,Goldhirsch A,Gandini S

    更新日期:2013-08-01 00:00:00

  • Significant inter- and intra-laboratory variation in grading of ductal carcinoma in situ of the breast: a nationwide study of 4901 patients in the Netherlands.

    abstract:PURPOSE:A considerable part of ductal carcinoma in situ (DCIS) lesions may never progress into invasive breast cancer. However, standard treatment consists of surgical excision. Trials aim to identify a subgroup of low-risk DCIS patients that can safely forgo surgical treatment based on histologic grade, which highligh...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-05082-y

    authors: van Dooijeweert C,van Diest PJ,Willems SM,Kuijpers CCHJ,Overbeek LIH,Deckers IAG

    更新日期:2019-04-01 00:00:00

  • Letrozole as primary medical therapy for locally advanced and large operable breast cancer.

    abstract:AIMS:To investigate the efficacy of letrozole 2.5 mg and 10 mg used as primary neoadjuvant therapy for patients with locally advanced and large operable breast cancer. PATIENTS AND METHODS:Twenty-four postmenopausal patients with locally advanced or large operable breast cancer were treated in two consecutive series w...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1010669403283

    authors: Dixon JM,Love CD,Bellamy CO,Cameron DA,Leonard RC,Smith H,Miller WR

    更新日期:2001-04-01 00:00:00

  • Amplifications of oncogene erbB-2 and chromosome 20q in breast cancer determined by differentially competitive polymerase chain reaction.

    abstract::A new method of measuring gene copy number in small samples of DNA was used to measure amplification of the erbB-2 gene and of chromosome 20q in breast cancer. This method, termed 'differentially competitive polymerase chain reaction' (DC-PCR) combines the advantages of two other techniques for measuring amplification...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806816

    authors: Deng G,Yu M,Chen LC,Moore D,Kurisu W,Kallioniemi A,Waldman FM,Collins C,Smith HS

    更新日期:1996-01-01 00:00:00

  • The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer.

    abstract::The basal-like or basal phenotype (BP) class of breast cancers have recently attracted attention as a poor prognostic form of breast cancer. However, BP appears to encompass biologically and clinically heterogeneous tumours, resulting in a lack of consensus definition of BP. We analysed 48,000 gene transcripts in 132 ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0450-x

    authors: Zhang H,Rakha EA,Ball GR,Spiteri I,Aleskandarany M,Paish EC,Powe DG,Macmillan RD,Caldas C,Ellis IO,Green AR

    更新日期:2010-05-01 00:00:00

  • Risk factors for inflammatory and non-inflammatory breast cancer in North Africa.

    abstract:PURPOSE:Studies of the etiology of inflammatory breast cancer (IBC), a rare but aggressive breast cancer, have been hampered by limited risk factor information. We extend previous studies by evaluating a broader range of risk factors. METHODS:Between 2009 and 2015, we conducted a case-control study of IBC at six cente...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05864-3

    authors: Schairer C,Hablas A,Eldein IAS,Gaafar R,Rais H,Mezlini A,Ayed FB,Ayoub WB,Benider A,Tahri A,Khouchani M,Aboulazm D,Karkouri M,Eissa S,Bastawisy AE,Yehia M,Gadalla SM,Swain SM,Merajver SD,Brown LM,Pfeiffer RM,Sol

    更新日期:2020-11-01 00:00:00

  • Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854).

    abstract::The tumor-stroma ratio has previously been shown to be prognostic for patients with invasive breast cancer. We present a validation study to assess the prognostic significance in lymph node-negative, premenopausal patients from the perioperative chemotherapy trial (POP trial, 10854) conducted by the European Organizat...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2571-5

    authors: Dekker TJ,van de Velde CJ,van Pelt GW,Kroep JR,Julien JP,Smit VT,Tollenaar RA,Mesker WE

    更新日期:2013-06-01 00:00:00

  • Current status of paclitaxel in the treatment of breast cancer.

    abstract::Paclitaxel is a highly active single agent as therapy for previously untreated as well as doxorubicin-refractory metastatic breast cancer, with associated response rates of 62% and 20-48%, respectively. Complete responses with paclitaxel occur chiefly in breast cancer patients whose metastatic disease has not been pre...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00666068

    authors: O'Shaughnessy JA,Cowan KH

    更新日期:1995-01-01 00:00:00

  • Identification of a novel mutations BRCA1*c.80 + 3del4 and BRCA2*c.6589delA in Slovak HBOC families.

    abstract::Mutations in the BRCA1 and BRCA2 genes account for the majority of hereditary breast ovarian cancer (HBOC) cases. However, after BRCA1 and BRCA2 screening still the most HBOC cases remain negative for any mutational event. Accordingly, in these cases raises the relevance to analyze the unusual BRCA1/2 variants of unce...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-0244-6

    authors: Konecny M,Vizvaryova M,Zavodna K,Behulova R,Gerykova Bujalkova M,Krivulcik T,Cisarik F,Kausitz J,Weismanova E

    更新日期:2010-01-01 00:00:00

  • Enumeration of circulating tumor cells in the blood of breast cancer patients after filtration enrichment: correlation with disease stage.

    abstract::The biological and clinical significance of circulating tumor cells (CTC) in the peripheral blood of breast cancer patients is not known. To study this question, we used a direct visualization assay to correlate the number of CTC with disease stage and progression. The CTC were enriched from the nucleated cell fractio...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/B:BREA.0000036897.92513.72

    authors: Kahn HJ,Presta A,Yang LY,Blondal J,Trudeau M,Lickley L,Holloway C,McCready DR,Maclean D,Marks A

    更新日期:2004-08-01 00:00:00

  • Comprehensive analysis of the homeobox family genes in breast cancer demonstrates their similar roles in cancer and development.

    abstract:BACKGROUND:The homeobox (HOX) family consists of 39 genes whose expressions are tightly controlled and coordinated within the family, during development. We performed a comprehensive analysis of this gene family in cancer settings. METHODS:Gene correlation analysis was performed using breast cancer data available in T...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-06087-2

    authors: Nakashoji A,Hayashida T,Yamaguchi S,Kawai Y,Kikuchi M,Yokoe T,Nagayama A,Seki T,Takahashi M,Kitagawa Y

    更新日期:2021-01-18 00:00:00

  • Fruits, vegetables and breast cancer risk: a systematic review and meta-analysis of prospective studies.

    abstract::Evidence for an association between fruit and vegetable intake and breast cancer risk is inconclusive. To clarify the association, we conducted a systematic review and meta-analysis of the evidence from prospective studies. We searched PubMed for prospective studies of fruit and vegetable intake and breast cancer risk...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s10549-012-2118-1

    authors: Aune D,Chan DS,Vieira AR,Rosenblatt DA,Vieira R,Greenwood DC,Norat T

    更新日期:2012-07-01 00:00:00

  • Refinement of breast cancer risk prediction with concordant leading edge subsets from prognostic gene signatures.

    abstract::Several prognostic signatures have been identified for breast cancer. However, these signatures vary extensively in their gene compositions, and the poor concordance of the risk groups defined by the prognostic signatures hinders their clinical applicability. Breast cancer risk prediction was refined with a novel appr...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3104-6

    authors: Huang CC,Tu SH,Lien HH,Huang CS,Huang CJ,Lai LC,Tsai MH,Chuang EY

    更新日期:2014-09-01 00:00:00

  • MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma.

    abstract::Node-positive breast carcinoma is associated with a poor prognosis. Some patients benefit from adjuvant chemotherapy but new treatment modalities should still be developed in order to further increase the cure rate in this patient group. Prognostic factors are needed to define patients for such studies. Here, the prog...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006326513176

    authors: Talvensaari-Mattila A,Pääkkö P,Turpeenniemi-Hujanen T

    更新日期:1999-12-01 00:00:00

  • Occult breast carcinoma in breast reduction specimens in European women.

    abstract::Breast reduction is a common surgical procedure performed by plastic and oncoplastic breast surgeons. The authors report on the incidence and management of cancer and atypical hyperplasia in breast reduction specimens from one institution over a 10-year period. All patients who underwent breast reduction surgery at No...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1589-9

    authors: Goyal A,Coulson SG,Wu JM,Suvarna SK,Reed MW,Caddy CM

    更新日期:2011-08-01 00:00:00

  • Growth kinetics of four human breast carcinomas grown in nude mice.

    abstract::The immune-deficient nude mouse with human tumor xenografts is an appropriate model system for performing detailed growth kinetic examinations. In the present study one estrogen and progesterone receptor-negative (T60) and three receptor-positive (Br-10, MCF-7, T61) human breast cancer xenografts in nude mice were inv...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01810740

    authors: Spang-Thomsen M,Rygaard K,Hansen L,Halvorsen AC,Vindeløv LL,Brünner N

    更新日期:1989-11-01 00:00:00

  • Genetic variants in trinucleotide repeat-containing 9 (TNRC9) are associated with risk of estrogen receptor positive breast cancer in a Chinese population.

    abstract::Trinucleotide repeat-containing 9 (TNRC9), a high mobility group chromatin-associated protein, has been implicated in breast cancer metastasis to the bone. Recently, several single nucleotide polymorphisms (SNPs) of TNRC9 were identified as novel breast cancer susceptibility loci by whole genome association studies, e...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-0809-z

    authors: Liang J,Chen P,Hu Z,Shen H,Wang F,Chen L,Li M,Tang J,Wang H,Shen H

    更新日期:2010-11-01 00:00:00